BECTON, DICKINSON AND COMPANY

(BDX)
  Report
Delayed Nyse  -  05/26 04:00:01 pm EDT
252.50 USD   +0.13%
05/19BD and Mitsubishi Gas Chemical have signed a letter of intent (LOI) to discuss a partnership agreement to explore new ways to advance biologic drug delivery
AQ
05/16BD Recognized by DiversityInc in Annual Ranking of Top US Companies for Diversity
AQ
05/13Embecta Fiscal Second-Quarter Results Fall on External Headwinds; Offers Downbeat Sales Outlook
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Becton, Dickinson and Company Receives 510(K) Clearance from the U.S. Food and Drug Administration for the BD Kiestra™ Identifa System

01/07/2022 | 06:50am EDT

Becton, Dickinson and Company announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD Kiestra™ IdentifA system, which is designed to automate the preparation of microbiology bacterial identification testing. Identifying the microorganism that is causing an infection is a labor-intensive process. With the BD Kiestra™ IdentifA, the lab technician uses BD Synapsys™ informatics to select discrete bacterial colonies from a digital plate image. Sophisticated robotics then physically pick those selected organisms and prepare the sample for specific identification testing. By automating what are typically cumbersome manual steps, the BD Kiestra™ IdentifA may reduce the potential for human error when preparing samples for bacterial identification and produce more accurate diagnoses for patients. Streamlining processes also enables lab technicians to focus their time and expertise on higher-value tasks. BD Kiestra™ IdentifA is the only FDA-cleared solution that is available as part of a track-connected system for lab automation to support specimen preparation workflows for routine and challenging isolate types. The integration of the BD Synapsys™ Informatics solution with the BD Kiestra™ IdentifA, in combination with matrix-assisted laser desorption/ionization-time of flight (MALDI-ToF) mass spectrometry, can yield more rapid and accurate identification of bacteria and yeasts to aid clinician treatment decisions.


© S&P Capital IQ 2022
All news about BECTON, DICKINSON AND COMPANY
05/19BD and Mitsubishi Gas Chemical have signed a letter of intent (LOI) to discuss a partne..
AQ
05/16BD Recognized by DiversityInc in Annual Ranking of Top US Companies for Diversity
AQ
05/13Embecta Fiscal Second-Quarter Results Fall on External Headwinds; Offers Downbeat Sales..
MT
05/12BD Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Pl..
PR
05/12Becton, Dickinson and Company Launches Fully Automated, High-Throughput Infectious Dise..
CI
05/11TRANSCRIPT : Becton, Dickinson and Company Presents at Bank of America 2022 Healthcare Con..
CI
05/11Babson, BD Expand Strategic Partnership to Advance Diagnostic Blood Collection in New C..
PR
05/11Babson Diagnostics, BD Expand Strategic Partnership to Advance Diagnostic Blood Collect..
CI
05/10INSIDER SELL : Becton Dickinson
MT
05/06Piper Sandler Adjusts Price Target on Becton Dickinson and Co. to $255 From $265, Maint..
MT
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2022 18 743 M - -
Net income 2022 1 746 M - -
Net Debt 2022 13 463 M - -
P/E ratio 2022 35,1x
Yield 2022 1,51%
Capitalization 71 979 M 71 979 M -
EV / Sales 2022 4,56x
EV / Sales 2023 4,32x
Nbr of Employees 75 000
Free-Float 77,6%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 252,50 $
Average target price 283,08 $
Spread / Average Target 12,1%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Christopher J. DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Joseph M. Smith Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY2.60%71 882
ABBOTT LABORATORIES-19.58%198 189
MEDTRONIC PLC2.02%141 586
HOYA CORPORATION-19.84%39 348
BAXTER INTERNATIONAL INC.-12.41%37 860
AMERISOURCEBERGEN CORPORATION15.19%32 314